Edwards Lifesciences Corporation (EW) : Traders are bullish on Edwards Lifesciences Corporation (EW) as it has outperformed the S&P 500 by a wide margin of 10.7% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.97%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.93% in the last 1 week, and is up 11.13% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Edwards Lifesciences Corp. is up 19.13% in the last 3-month period. Year-to-Date the stock performance stands at 49.49%. The stock has recorded a 20-day Moving Average of 4.84% and the 50-Day Moving Average is 11.48%.
Edwards Lifesciences Corporation (NYSE:EW): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $114.96 and $114.94 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $118.26. The buying momentum continued till the end and the stock did not give up its gains. It closed at $118.07, notching a gain of 2.71% for the day. The total traded volume was 3,792,273 . The stock had closed at $114.95 on the previous day.
Also, JMP Securities maintains its view on Edwards Lifesciences Corporation (NYSE:EW) according to the research report released by the firm to its investors. The shares have now been rated Market Outperform by the stock experts at the ratings house. JMP Securities raises the price target from $125 per share to $130 per share on Edwards Lifesciences Corporation. The rating by the firm was issued on July 28, 2016.
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.